[the EFTA Court ruling, here, discussed on this weblog here] considers, in the context of a salmon virus vaccine, the important issues of what types of marketing authorisations count for the purposes of determining whether a supplementary protection certificate (SPC) is available and what its duration is, and whether an SPC based on a particular authorised biological product can validly extend protection to an authorised variant of that product. Possible implications with respect to SPCs for human biological medicines are also discussed.This is followed by a case analysis by Katie Hutchinson and Laura Reynolds (Bristows), "CJEU rules again on combination SPCs - Actavis v Boehringer". Explains the journal:
This comment considers the latest judgment from the CJEU on combination SPCs. It summarises earlier cases from the court in order to build up a picture of the position the CJEU is now taking.Further details of the journal can be accessed here.